COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS
Universite De La Mediterranee Aix-Marseille II;Universidad De Oviedo;Assistance Publique Hopitaux De Marseille;Association Francaise Contre Les Myopathies (AFM)
发明人:
Nicolas Levy,Pierre Cau,Carlos Lopez-Otin
申请号：
US13922055
公开号：
US20130281408A1
申请日:
2013.06.19
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
